How much profit has Basilea Pharmaceutica AG Allschwil made this year?
Basilea Pharmaceutica AG Allschwil has made 47.75 M CHF this year.
Basilea Pharmaceutica AG Allschwil Net Income 2024
Basilea Pharmaceutica AG Allschwil Net Income
47.75 M CHF
Ticker
BSLN.SW
ISIN
CH0011432447
WKN
A0B9GA
In 2024, Basilea Pharmaceutica AG Allschwil's profit amounted to 47.75 M CHF, a 356.89% increase from the 10.45 M CHF profit recorded in the previous year.
The Basilea Pharmaceutica AG Allschwil Net Income history
| YEAR | NET INCOME (undefined CHF) |
|---|---|
| 2028e | 75.84 |
| 2027e | 77.42 |
| 2026e | 63.22 |
| 2025e | 42.89 |
| 2024e | 47.75 |
| 2023 | 10.45 |
| 2022 | 12.15 |
| 2021 | -6.83 |
| 2020 | -14.72 |
| 2019 | -22.42 |
| 2018 | -31.35 |
| 2017 | -19.36 |
| 2016 | -51.29 |
| 2015 | -61.6 |
| 2014 | -41.55 |
| 2013 | -33 |
| 2012 | -53 |
| 2011 | -57.6 |
| 2010 | 107.6 |
| 2009 | -120.7 |
| 2008 | -143.5 |
| 2007 | -126.8 |
| 2006 | -85.1 |
| 2005 | -49.6 |
| 2004 | -75.5 |
Basilea Pharmaceutica AG Allschwil Revenue, EBIT, Net Income CH0011432447 · A0B9GA
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Basilea Pharmaceutica AG Allschwil, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Basilea Pharmaceutica AG Allschwil from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Basilea Pharmaceutica AG Allschwil’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Basilea Pharmaceutica AG Allschwil. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Basilea Pharmaceutica AG Allschwil’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Basilea Pharmaceutica AG Allschwil’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Basilea Pharmaceutica AG Allschwil’s growth potential.
Basilea Pharmaceutica AG Allschwil Revenue, EBIT and net profit per share
| Date | Basilea Pharmaceutica AG Allschwil Revenue | Basilea Pharmaceutica AG Allschwil EBIT | Basilea Pharmaceutica AG Allschwil Net Income |
|---|---|---|---|
| 2028e | 217.95 M undefined | 85 M undefined | 75.84 M undefined |
| 2027e | 239.91 M undefined | 91.16 M undefined | 77.42 M undefined |
| 2026e | 254.81 M undefined | 79.41 M undefined | 63.22 M undefined |
| 2025e | 222.44 M undefined | 51.04 M undefined | 42.89 M undefined |
| 2024e | 204.07 M undefined | 42.08 M undefined | 47.75 M undefined |
| 2023 | 157.63 M undefined | 19.21 M undefined | 10.45 M undefined |
| 2022 | 147.77 M undefined | 18.54 M undefined | 12.15 M undefined |
| 2021 | 148.12 M undefined | 1.17 M undefined | -6.83 M undefined |
| 2020 | 127.63 M undefined | -23.26 M undefined | -14.72 M undefined |
| 2019 | 134.38 M undefined | -17.2 M undefined | -22.42 M undefined |
| 2018 | 132.56 M undefined | -24.1 M undefined | -31.35 M undefined |
| 2017 | 101.52 M undefined | -17.05 M undefined | -19.36 M undefined |
| 2016 | 65.98 M undefined | -43.89 M undefined | -51.29 M undefined |
| 2015 | 51.65 M undefined | -61.49 M undefined | -61.6 M undefined |
| 2014 | 42.5 M undefined | -41.83 M undefined | -41.55 M undefined |
| 2013 | 41 M undefined | -33.3 M undefined | -33 M undefined |
| 2012 | 57.9 M undefined | -50.8 M undefined | -53 M undefined |
| 2011 | 66.7 M undefined | -57.3 M undefined | -57.6 M undefined |
| 2010 | 116.2 M undefined | -16.5 M undefined | 107.6 M undefined |
| 2009 | 26.5 M undefined | -120.3 M undefined | -120.7 M undefined |
| 2008 | 11.8 M undefined | -152.5 M undefined | -143.5 M undefined |
| 2007 | 7.9 M undefined | -136.5 M undefined | -126.8 M undefined |
| 2006 | 7.4 M undefined | -87.9 M undefined | -85.1 M undefined |
| 2005 | 30.5 M undefined | -50.8 M undefined | -49.6 M undefined |
| 2004 | 300,000 undefined | -75.7 M undefined | -75.5 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 300,000 CHF | -75.7 M CHF | -75.5 M CHF |
| 2005 | 30.5 M CHF | -50.8 M CHF | -49.6 M CHF |
| 2006 | 7.4 M CHF | -87.9 M CHF | -85.1 M CHF |
| 2007 | 7.9 M CHF | -136.5 M CHF | -126.8 M CHF |
| 2008 | 11.8 M CHF | -152.5 M CHF | -143.5 M CHF |
| 2009 | 26.5 M CHF | -120.3 M CHF | -120.7 M CHF |
| 2010 | 116.2 M CHF | -16.5 M CHF | 107.6 M CHF |
| 2011 | 66.7 M CHF | -57.3 M CHF | -57.6 M CHF |
| 2012 | 57.9 M CHF | -50.8 M CHF | -53 M CHF |
| 2013 | 41 M CHF | -33.3 M CHF | -33 M CHF |
| 2014 | 42.5 M CHF | -41.83 M CHF | -41.55 M CHF |
| 2015 | 51.65 M CHF | -61.49 M CHF | -61.6 M CHF |
| 2016 | 65.98 M CHF | -43.89 M CHF | -51.29 M CHF |
| 2017 | 101.52 M CHF | -17.05 M CHF | -19.36 M CHF |
| 2018 | 132.56 M CHF | -24.1 M CHF | -31.35 M CHF |
| 2019 | 134.38 M CHF | -17.2 M CHF | -22.42 M CHF |
| 2020 | 127.63 M CHF | -23.26 M CHF | -14.72 M CHF |
| 2021 | 148.12 M CHF | 1.17 M CHF | -6.83 M CHF |
| 2022 | 147.77 M CHF | 18.54 M CHF | 12.15 M CHF |
| 2023 | 157.63 M CHF | 19.21 M CHF | 10.45 M CHF |
| 2024e | 204.07 M CHF | 42.08 M CHF | 47.75 M CHF |
| 2025e | 222.44 M CHF | 51.04 M CHF | 42.89 M CHF |
| 2026e | 254.81 M CHF | 79.41 M CHF | 63.22 M CHF |
| 2027e | 239.91 M CHF | 91.16 M CHF | 77.42 M CHF |
| 2028e | 217.95 M CHF | 85 M CHF | 75.84 M CHF |
Basilea Pharmaceutica AG Allschwil stock margins CH0011432447 · A0B9GA
The Basilea Pharmaceutica AG Allschwil margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Basilea Pharmaceutica AG Allschwil. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Basilea Pharmaceutica AG Allschwil.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Basilea Pharmaceutica AG Allschwil's sales revenue. A higher gross margin percentage indicates that the Basilea Pharmaceutica AG Allschwil retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Basilea Pharmaceutica AG Allschwil's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Basilea Pharmaceutica AG Allschwil's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Basilea Pharmaceutica AG Allschwil's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Basilea Pharmaceutica AG Allschwil. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Basilea Pharmaceutica AG Allschwil's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Basilea Pharmaceutica AG Allschwil Margin History
| Basilea Pharmaceutica AG Allschwil Gross margin | Basilea Pharmaceutica AG Allschwil Profit margin | Basilea Pharmaceutica AG Allschwil EBIT margin | Basilea Pharmaceutica AG Allschwil Profit margin |
|---|---|---|---|
| 2028e | 83 % | 39 % | 34.8 % |
| 2027e | 83 % | 38 % | 32.27 % |
| 2026e | 83 % | 31.16 % | 24.81 % |
| 2025e | 83 % | 22.95 % | 19.28 % |
| 2024e | 83 % | 20.62 % | 23.4 % |
| 2023 | 83 % | 12.18 % | 6.63 % |
| 2022 | 83.35 % | 12.55 % | 8.22 % |
| 2021 | 83.75 % | 0.79 % | -4.61 % |
| 2020 | 81.15 % | -18.22 % | -11.53 % |
| 2019 | 85.96 % | -12.8 % | -16.69 % |
| 2018 | 84.69 % | -18.18 % | -23.65 % |
| 2017 | 91.11 % | -16.79 % | -19.07 % |
| 2016 | 91.9 % | -66.51 % | -77.73 % |
| 2015 | 83 % | -119.03 % | -119.26 % |
| 2014 | 83 % | -98.43 % | -97.76 % |
| 2013 | 100 % | -81.22 % | -80.49 % |
| 2012 | 92.4 % | -87.74 % | -91.54 % |
| 2011 | 96.4 % | -85.91 % | -86.36 % |
| 2010 | 98.02 % | -14.2 % | 92.6 % |
| 2009 | 93.96 % | -453.96 % | -455.47 % |
| 2008 | 97.46 % | -1,292.37 % | -1,216.1 % |
| 2007 | 100 % | -1,727.85 % | -1,605.06 % |
| 2006 | 83 % | -1,187.84 % | -1,150 % |
| 2005 | 83 % | -166.56 % | -162.62 % |
| 2004 | 83 % | -25,233.33 % | -25,166.67 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 83 % | -25,233.33 % | -25,166.67 % |
| 2005 | 83 % | -166.56 % | -162.62 % |
| 2006 | 83 % | -1,187.84 % | -1,150 % |
| 2007 | 100 % | -1,727.85 % | -1,605.06 % |
| 2008 | 97.46 % | -1,292.37 % | -1,216.1 % |
| 2009 | 93.96 % | -453.96 % | -455.47 % |
| 2010 | 98.02 % | -14.2 % | 92.6 % |
| 2011 | 96.4 % | -85.91 % | -86.36 % |
| 2012 | 92.4 % | -87.74 % | -91.54 % |
| 2013 | 100 % | -81.22 % | -80.49 % |
| 2014 | 83 % | -98.43 % | -97.76 % |
| 2015 | 83 % | -119.03 % | -119.26 % |
| 2016 | 91.9 % | -66.51 % | -77.73 % |
| 2017 | 91.11 % | -16.79 % | -19.07 % |
| 2018 | 84.69 % | -18.18 % | -23.65 % |
| 2019 | 85.96 % | -12.8 % | -16.69 % |
| 2020 | 81.15 % | -18.22 % | -11.53 % |
| 2021 | 83.75 % | 0.79 % | -4.61 % |
| 2022 | 83.35 % | 12.55 % | 8.22 % |
| 2023 | 83 % | 12.18 % | 6.63 % |
| 2024e | 83 % | 20.62 % | 23.4 % |
| 2025e | 83 % | 22.95 % | 19.28 % |
| 2026e | 83 % | 31.16 % | 24.81 % |
| 2027e | 83 % | 38 % | 32.27 % |
| 2028e | 83 % | 39 % | 34.8 % |
Basilea Pharmaceutica AG Allschwil Aktienanalyse
What does Basilea Pharmaceutica AG Allschwil do?
Basilea Pharmaceutica AG is a leading biopharmaceutical company based in Basel, Switzerland. It was founded in 2000 and focuses on the research, development, and marketing of innovative drugs for the treatment of infectious diseases, cancer, and dermatological conditions. The company operates globally and currently employs over 200 employees. Basilea's main focus is on developing drugs that meet the specific needs of patients and medical professionals. It works closely with its partners and customers to ensure that its products meet the highest quality standards and meet the demands of patients. Basilea has two main divisions: infections and oncology. The company has a strong expertise in the development of antibiotics and antifungal drugs. One of its most well-known products is the antibiotic Ceftobiprol, which is used to treat bacterial infections such as pneumonia, skin, and bone infections. Another promising product is Isavuconazole, an antifungal drug used to treat fungal infections. In oncology, the business is divided into two important areas: the development and marketing of cancer drugs, and collaboration with other companies to develop tailored cancer therapies. The company works closely with other leading companies such as Pfizer, Roche, and GSK to expand its expertise in cancer research and development. Basilea's business model is based on the development of innovative drugs that meet the needs of patients and doctors. The company invests heavily in its research and development and aims to develop ethically sound and effective solutions for controlling infectious diseases and cancer. Through strategic partnerships and targeted marketing, it works to market its products worldwide and strengthen its position in the rapidly changing pharmaceutical market. Basilea sees itself as an innovative company that establishes itself in the market and plays a leading role in the industry. Its success is based on the concept of innovation, commitment, and growth. The company is committed to improving the quality of life for patients around the world by focusing on the development of new drugs that help fulfill important medical needs. Basilea Pharmaceutica AG remains committed to striving for excellence and innovation together with its partners and customers to advance the development of new treatment options. With this focus, Basilea will continue to play an important role in the industry and bring innovative drugs to the market that improve patients' lives and make the world a better place. Basilea Pharmaceutica AG Allschwil ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding Basilea Pharmaceutica AG Allschwil's Profit Margins
The profit margins of Basilea Pharmaceutica AG Allschwil represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Basilea Pharmaceutica AG Allschwil's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Basilea Pharmaceutica AG Allschwil's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Basilea Pharmaceutica AG Allschwil's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Basilea Pharmaceutica AG Allschwil’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Basilea Pharmaceutica AG Allschwil stock
How has the profit developed compared to last year?
The profit has increased by 356.89% compared to last year increased
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Basilea Pharmaceutica AG Allschwil publish its earnings?
Basilea Pharmaceutica AG Allschwil publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Basilea Pharmaceutica AG Allschwil?
The profits of Basilea Pharmaceutica AG Allschwil are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Basilea Pharmaceutica AG Allschwil?
You can learn more about the earnings of Basilea Pharmaceutica AG Allschwil by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Basilea Pharmaceutica AG Allschwil pay?
Over the past 12 months, Basilea Pharmaceutica AG Allschwil paid a dividend of 5 CHF . This corresponds to a dividend yield of about 12.47 %. For the coming 12 months, Basilea Pharmaceutica AG Allschwil is expected to pay a dividend of 0 CHF.
What is the dividend yield of Basilea Pharmaceutica AG Allschwil?
The current dividend yield of Basilea Pharmaceutica AG Allschwil is 12.47 %.
When does Basilea Pharmaceutica AG Allschwil pay dividends?
Basilea Pharmaceutica AG Allschwil pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Basilea Pharmaceutica AG Allschwil?
Basilea Pharmaceutica AG Allschwil paid dividends every year for the past 0 years.
What is the dividend of Basilea Pharmaceutica AG Allschwil?
For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.
In which sector is Basilea Pharmaceutica AG Allschwil located?
Basilea Pharmaceutica AG Allschwil is assigned to the 'Health' sector.
Wann musste ich die Aktien von Basilea Pharmaceutica AG Allschwil kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Basilea Pharmaceutica AG Allschwil from 6/21/2013 amounting to 5 CHF, you needed to have the stock in your portfolio before the ex-date on 4/11/2013.
When did Basilea Pharmaceutica AG Allschwil pay the last dividend?
The last dividend was paid out on 6/21/2013.
What was the dividend of Basilea Pharmaceutica AG Allschwil in the year 2023?
In the year 2023, Basilea Pharmaceutica AG Allschwil distributed 0 CHF as dividends.
In which currency does Basilea Pharmaceutica AG Allschwil pay out the dividend?
The dividends of Basilea Pharmaceutica AG Allschwil are distributed in CHF.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Basilea Pharmaceutica AG Allschwil
Our stock analysis for Basilea Pharmaceutica AG Allschwil Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Basilea Pharmaceutica AG Allschwil Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Basilea Pharmaceutica AG Allschwil Revenue
- Basilea Pharmaceutica AG Allschwil Net Income
- Basilea Pharmaceutica AG Allschwil P/E
- Basilea Pharmaceutica AG Allschwil P/S
- Basilea Pharmaceutica AG Allschwil EBIT
- Basilea Pharmaceutica AG Allschwil Dividend
- Basilea Pharmaceutica AG Allschwil Stocks
- Basilea Pharmaceutica AG Allschwil Market capitalization
- Basilea Pharmaceutica AG Allschwil Debt
- Basilea Pharmaceutica AG Allschwil Liabilities
- Basilea Pharmaceutica AG Allschwil Equity
- Basilea Pharmaceutica AG Allschwil AAQS
- Basilea Pharmaceutica AG Allschwil Employees
- Basilea Pharmaceutica AG Allschwil ROE
- Basilea Pharmaceutica AG Allschwil ROA
- Basilea Pharmaceutica AG Allschwil ROCE
